United States· US:61958-2301_175f5d1a-aae9-43d5-b004-65eefec167d4
VEMLIDY
A tenofovir alafenamide product containing tenofovir alafenamide fumarate, registered in United States by Gilead Sciences, Inc.. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Tenofovir alafenamide is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AF13 (tenofovir alafenamide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Tenofovir alafenamide · ATC J05AF13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tenofovir alafenamide costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tenofovir alafenamide · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.29
- IT Italy$18.37
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TENOFOVIR ALAFENAMIDE FUMARATE
- Manufacturer
- Gilead Sciences, Inc.
- Country
- United States (US)
- ATC code
- J05AF13
- ATC class
- Tenofovir alafenamide
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11619582301130 TABLET in 1 BOTTLE, PLASTIC (61958-2301-1)
- ndc1161958-2301-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tenofovir alafenamide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaVEMLIDYGILEAD SCIENCES CANADA INC
- United KingdomVemlidy 25mg tabletsGilead Sciences Ltd
- FinlandVemlidyOrifarm Oy
- NorwayVemlidyGilead Sciences Ireland UC
- CzechiaVEMLIDYGilead Sciences Ireland UC, Carrigtohill
- BelgiumGenvoya 90 mg - 90 mg - 120 mg - 6 mgGilead Sciences Ireland UC
- IrelandVemlidy 25 mg film-coated tabletsGilead Sciences Ireland UC
- IcelandVemlidyGilead Sciences Ireland UC*
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- Germany · Tenofoviralafenamid Devatis
- Iceland · Vemlidy
- Liechtenstein · Vemlidy
- Netherlands · Tenofoviralafenamide Devatis
- Norway · Vemlidy
- Portugal · Tenofovir Alafenamida Humanis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c8959e43-dfcb-4482-89e3-3a4ecc78750f GET /v1/drugs/c8959e43-dfcb-4482-89e3-3a4ecc78750f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "25",
"substance": "TENOFOVIR ALAFENAMIDE FUMARATE",
"productndc": "61958-2301",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA208464",
"marketing_category": "NDA"
}See everything about tenofovir alafenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.